Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia

Leukemia

Volumn 12, Issue 4, 1998, Pages 455-462

  Cortes, J ^a   Fayad, L ^a   Kantarjian, H ^a   O'Brien, S ^a   Lee, M S ^a   Talpaz, M ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; HLA; Interferon alpha

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CELL PROTEIN; HLA A ANTIGEN; HLA B ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; GENETIC ASSOCIATION; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031981132     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400965     Document Type: Article

References (9)

1. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-poisitive leukemias. New Engl J Med 1988; 319: 990-998.
2. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069-3081.
3. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
4. Kantarjian HM, Smith T, O'Brien S, Berah M, Pierce S, Talpaz M and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
5. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
6. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. J Clin Invest 1994; 94: 1383-1389.
7. Gutterman JU. Cytokine therapeutics: lessons from interferon-α. Proc Nat Acad Sci USA 1994; 91: 1198-1205.
8. Barrett A, Jiang YZ. Immune responses to chronic myeloid leukemia. Bone Marrow Transplant 1992; 9: 305-311.
9. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK. The interferons: mechanisms of action and clinical applications. JAMA 1991; 266: 1375-1383.